31
May

AbbVie’s experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 combined with rituximab registered an 84% overall response rate among patients with chronic lymphocytic leukemia.

…read more

Source: AbbVie’s leukemia drug program continues to wow analysts in early study

    

0 No comments